Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating Expenses:    
Research and Development $ 1,280,242 $ 938,041
General and Administrative 1,300,143 1,032,603
Total Operating Expenses 2,580,385 1,970,644
Operating Loss Before Other Income, Net (2,580,385) (1,970,644)
Other (Loss) Income, Net:    
Interest Income 250 18,444
Interest Expense (686)  
Total Other (Loss) Income, Net (436) 18,444
Net Loss $ (2,580,821) $ (1,952,200)
Net Loss Per Common Share - Basic and Diluted $ (0.37) $ (0.43)
Weighted-Average Shares Outstanding - Basic and Diluted 6,954,438 4,524,738
Net Loss $ (2,580,821) $ (1,952,200)
Other Comprehensive Loss:    
Foreign Currency Translation Adjustments 10,473 188
Comprehensive Loss $ (2,570,348) $ (1,952,012)